Product Description
Mechanisms of Action: Radiopharmaceutical
Novel Mechanism: Yes
Modality: Radiopharmaceutical
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: First Affiliated Hospital of Wannan Medical College
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500095162 |
ChiCTR2500095162 | N/A |
Not yet recruiting |
Prostate Cancer |
2027-01-02 |
|||
CTR20260485 |
CTR20260485 | N/A |
Unknown |
Prostate Cancer |
None |
2026-02-12 |
Treatments |
|
NCT07117760 |
FirstAHFujian-225Ac-LNC1011 | P2 |
Recruiting |
Prostate Cancer |
2027-12-31 |
2025-08-13 |
Primary Endpoints|Treatments |
|
NCT07363486 |
Sequential Study-225Ac-LNC1011 | P2 |
Recruiting |
Prostate Cancer |
2026-12-31 |
2026-01-24 |
Recent News Events
Date |
Type |
Title |
|---|